(123 days)
Not Found
No
The document describes image acquisition, processing, display, and saving, along with post-processing features like frame averaging, calipers, 3D view, and reporting. There is no mention of AI, ML, or related concepts like algorithms for automated analysis, classification, or prediction based on the images. The performance studies focus on safety, electrical/optical standards, and image quality, not on the performance of any AI/ML model.
No.
The device is described as an imaging system intended as an aid in diagnosis, not for treatment.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that the device "is indicated for use as an aid in the diagnosis of physiologic and pathologic conditions of the eye".
No
The device description explicitly states that the system includes an optical engine, a scanning head, an interchangeable lens set, a computer, and software. This indicates the presence of significant hardware components beyond just software.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze samples taken from the human body (like blood, urine, tissue biopsies) in vitro (outside the body).
- This device is an in vivo imaging system. It directly images the eye within the patient's body using light.
- The intended use and device description clearly state it acquires images of ocular tissue microstructure through non-contact optical imaging. This is a direct imaging technique, not an analysis of a sample.
Therefore, the Bioptigen Envisu™ Spectral Domain Ophthalmic Imaging System (SDOIS) is a medical imaging device, not an IVD.
N/A
Intended Use / Indications for Use
Bioptigen Envisu™ Spectral Domain Ophthalmic Imaging System (SDOIS) is intended to acquire, process, display and save depth-resolved images of ocular tissue microstructure using Spectral Domain Optical Coherence Tomography (SD-OCT).
The Envisu SDOIS is indicated for use as an aid in the diagnosis of physiologic and pathologic conditions of the eye through non-contact optical imaging of the various tissues of the eye is supported through the use of interchangeable lenses. It is indicated for use on patient populations from premature and neonatal infants to adult, and is suitable for patients ambulatory or confined. The system is indicated for use in upright or supine imaging, handheld or mounted, and is suited for imaģing patients under anesthesia.
Product codes (comma separated list FDA assigned to the subject device)
HLI, OBO
Device Description
The Envisu™ SDOIS is a non-contact, non-invasive and mobile ophthalmic imaging device that can be used to view ocular tissue physiology and pathology through the interaction of light with the optical scattering properties of structures of the eye.
Like its predicate, the Envisu™ Spectral Domain Ophthalmic Imaging System (SDOIS) is a nearinfrared scanning imaging medical device designed to capture depth-resolved images of ocular tissue microstructure. It is available in "high (HR)" and "very-high (VHR)" resolution based on the SLED light source chosen. Each option includes an optical engine, a scanning head, an interchangeable lens set, a computer and the InVivoVue™ Clinic software for imaging of ocular tissue microstructures. The smaller system footprint and mobile security cart easily accommodate any clinical environment.
The optical engine includes a low power broadband LED light source with bandwidths of 40 - 100 nm operating in the wavelength range between 760 - 930 nm and a spectrometer that detects backscattered radiation. The scanning head is flexibly designed to be used mounted or handheld for the mutual convenience and comfort of patient and ciinician. Handheld use of the light-weight (
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
0
New Traditional 510(k)
bioptigen
MAY 1 1 2012
510(K) SUMMARY (PER 21 CFR 807.92) -
Date Prepared: December 23, 2011
SUBMITTER INFORMATION
| 510(k) Owner and Device Manufacturer: | Bioptigen, Inc. |
|---|---|
| Registration Number: | 3006809695 |
| Address: | 104 T.W. Alexander, Building 2, Durham, NC 27709 |
| Phone: | +1 919 314 5500 |
| Fax: | +1 919 314 5501 |
Contact:
Dawn Reilly-O'Dell, RAC Full Circle Regulatory Consulting, LLC +1 919 410 7497 (Phone) dreilly@bioptigen.com (Email)
DEVICE IDENTIFICATION
Trade or proprietary name:
Envisu™ Spectral Domain Ophthalmic Imaging System (SDOIS) Spectral Domain Optical Coherence Tomography (SD-OCT) Common or usual name: Ophthalmoscope, AC-powered; Classification name: Tomography, Optical Coherence ни, ово Product Codes: 886.1570 Regulation Number:
INTENDED USE
Bioptigen Envisu™ Spectral Domain Ophthalmic Imaging System (SDOIS) is intended to acquire, process, display and save depth-resolved images of ocular tissue microstructure using Spectral Domain Optical Coherence Tomography (SD-OCT).
The Envisu SDOIS is indicated for use as an aid in the diagnosis of physiologic and pathologic conditions of the eye through non-contact optical imaging of the various tissues of the eye is supported through the use of interchangeable lenses. It is indicated for use on patient populations from premature and neonatal infants to adult, and is suitable for patients ambulatory or confined. The system is indicated for use in upright or supine imaging, handheld or mounted, and is suited for imaģing patients under anesthesia.
1
New Traditional 510(k)
bioptigen
SUBSTANTIAL EQUIVALENCE
The Envisu™ SDOIS is substantially equivalent to the predicate SDOIS in technology, safety and effectiveness. The Envisu™ SDOIS incorporates a number of design changes, but it shares the same fundamental spectral domain optical coherence tomography imaging technology and incoherent superluminiscent light emitting diode technology as the predicate SDOIS. The differences between the 2006 predicate, K063343, and the current subject SDOIS are the following design modifications incorporated to enhance device usability and performance:
- . Upgraded spectrometer line-scan camera allowing 32,000 A-scans/second for faster imaging speeds with no increase in patient irradiance
- . Added VHR light source option for improved axial resolution without increase in patient irradiant exposure
- . Revised scan head with enhanced ergonomics including handheld operation for improved clinical flexibility and patient comfort
- Mobile transport cart with Uninterruptable Power Supply (UPS)
- . Increased computer memory and processing speed
- . Additional objective lens options for cornea and related anterior imaging
- Updated Information for Use labeling to parallel the system changes and a new training manual to address use of the handheld scanner
- Added spectrometer design option for increased imaging depth to 3.4 mm in air (2.5 mm in tissue) for greater depth of imaging field
- . Upgraded IVVC software post-processing and visualization functionality including four new. features, which are the option to register and average multiple frames, the manual Onscreen Calipers, the 3D view and the option to generate Word-based reports
| Predicate Device | 510(k) Holder | 510(k) | Clearance Date |
|---|---|---|---|
| Spectral Domain Ophthalmic Imaging System (SDOIS) . | Bioptigen, Inc. | K063343 | December 13, 2006 |
2
New Traditional 510(k)
Envisu SDOIS
bioptigen
Predicate
SDOIS
Technological Comparison:
Medical Device
Indications for Use
Spectral Domain Imaging The System (SDOIS) is intended to acquire, process, display and save depth-resolved images of ocular microstructure tissue using Spectral Domain Optical Coherence Tomography (SD-OCT). It is primarily intended for the imaging of retinal tissue, but the cornea, sclera and conjunctiva can also be imaged by changing the focal position. Indications for use evaluation include the of ophthalmic tissue in routine clinical examinations and as an aid in the diagnosis of conditions that affect the optical scattering properties of ocular tissue.
Subject Envisu™ SDOIS
Bioptigen Envisu™ Spectral Domain Ophthalmic Imaging system is intended to acquire, process, display and save depth-resolved images of ocular tissue microstructure using Spectral Domain Optical Coherence Tomography (SDOCT). The Envisu™ SDOIS is indicated for use as an aid in the diagnosis of physiologic and pathologic conditions of the eye through non-contact optical imaging. Imaging of the various tissues of the eye is supported through the use of interchangeable lenses. It is indicated for use on patient populations from premature and neonatal infants to adult, and is suitable for patients ambulatory or confined. The system is indicated for use in upright or supine imaging, handheld or mounted, and is suited for imaging patients under anesthesia.
Categories
Method of Operation Light Source
Light Source Classification
Optical Power
Resolution, Lateral
Resolution, Axial
Depth Range (in tissue/air)
Scanner Type
Specifications
| SD-OCT | Same as predicate | |
|---|---|---|
| SLED | SLED | |
| High Resolution (HR) | HR: Same as predicate | |
| VHR: Very High Resolution | ||
| Class 1 LED | HR: Same as predicate | |
| VHR: Class 1 LED | ||
| 1 Values are approximate, based on an average refractive index of 1.38 |
5
Image /page/5/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is an abstract image of an eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
MAY 1 1 2012
Bioptigen, Inc. c/o Ms. Dawn Reilly-O'Dell, RAC Principal Consultant Full Circle Regulatory Consulting, LLC 104 T.W. Alexander Drive, P.O. Box 13569 Durham, North Carolina 27709
Re: K120057
Trade/Device Name: Envisu Spectral Domain Opthalmic Imaging System (SDOIS) C2200 and C2300 Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Codes: HLI, OBO Dated: May 4, 2012 Received: May 7, 2012
Dear Ms. Reilly-O'Dell:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
6
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
机_
Sincerely yours,
Kesia Alexander
Malvina B. Evdelman, M.D. Director Division of Ophthalmic, Neurological, and Ear. Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
INDICATIONS FOR USE STATEMENT
510(k) Number (if known):
Device Name:
Envisu "M SDOIS (Spectral Domain Ophthalmic Imaging System)
Indications for Use:
Bioptigen Envisu™ Spectral Domain Ophthalmic Imaging System (Envisu™ SDOIS) is intended to acquire, process, display and save depth-resolved images of ocular tissue microstructure using Spectral Domain Optical Coherence Tomography (SDOCT). The Envisu™ SDOIS is indicated for use as an aid in the diagnosis of physiologic and pathologic conditions of the eye through non-contact optical imaging. Imaging of the various tissues of the eye is supported through the use of interchangeable lenses. It is indicated for use on patient populations from premature and neonatal infants to adult, and is suitable for patients ambulatory or confined. The system is indicated for use in upright or supine imaging, handheld or mounted, and is suited for imaging patients under anesthesia.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 of 1
(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices
K120057
310(k) Number
Bioptigen, Inc. ~ Confidential
Page 189 of 176